Skip to main content
. 2023 Oct 19;23:702. doi: 10.1186/s12879-023-08691-1

Table 8.

Comparison between genotypes (CXCL12 rs2839693) according to treatment and outcomes

CXCL12 rs2839693
CC
(n = 209)
CT + TT
(n = 91)
OR (95%CI) P value* CC
(n = 209)
CT
(n = 84)
TT
(n = 7)
P value*
No. (%) No. (%) No. (%) No.(%) No.(%)
Antibiotic 203(97.1) 85(93.4) 0.42(0.13–1.34) &0.196 203(97.1) 78(92.9) 7(100) &0.207
Antifungal 12(5.7) 6(6.6) 1.16(0.42–3.19) &0.794 12(5.7) 6(7.1) 0(0) &0.717
Antiviral 155(74.2) 77(84.6) 1.92(1.00–3.66) &0.052 155(74.2) 71(84.5) 6(85.7) &0.138
Glucocorticoids 116(55.5) 60(65.9) 1.55(0.93–2.59) 0.099 116(55.5) 55(65.5) 5(71.4) &0.230
Clexane 57(27.3) 35(38.5) 1.67(0.99–2.81) &0.058 57(27.3) 30(35.7) 5(71.4) &0.022*
Oxygen therapy
 None 64(30.6) 9(9.9) 0.25(0.12–0.53) & < 0.001* 64(30.6) 9(10.7) 0(0) & < 0.001*
 Nasal cannula 43(20.6) 35(38.5) 2.41(1.41–4.14) &0.002* 43(20.6) 29(34.5) 6(85.7) & < 0.001*
 Mask oxygen 96(45.9) 54(59.3) 1.72(1.04–2.83) &0.044* 96(45.9) 50(59.5) 4(57.1) &0.102
 Invasive mechanical ventilation 8(3.8) 10(11.0) 3.10(1.18–8.14) &0.031* 8(3.8) 10(11.9) 0(0) &0.025*
Outcomes
 Home management 65(31.1) 13(14.3) 0.37(0.19–0.71) &0.002* 65(31.1) 13(15.5) 0(0) &0.006*
 Hospitalization without ICU 61(29.2) 17(18.70 0.56(0.30–1.02) &0.063 61(29.2) 17(20.2) 0(0) &0.082
 ICU 83(39.7) 61(67.0) 3.09(1.84–5.18) & < 0.001* 83(39.7) 54(64.3) 7(100) & < 0.001*
 Death 21(10.0) 18(19.8) 2.21(1.11–4.38) &0.026* 21(10.0) 13(15.5) 5(71.4) & < 0.001*
Duration of ICU stay (days)
 Median( Range) 8.00(1–13) 7.00(1–13) ------ §0.284 8.00(1–13) 6.50(1–13) 9.00(1–12) §0.159
Duration of in-hospital stay (days)
 Median(Range) 7.50(1–15) 7.00(1–15) ------ §0.856 7.50(1–15) 7.00(1–15) 12.00(6–15) §0.035*
Duration of recovery (days)
 Median (Range) 18.00(2–48) 15.00(2–48) ------ §0.703 18.00(2–48) 15.00(2–48) 23.50(2–44) §0.930

§Mann Whitney test

&Fisher's Exact test. p values represent statistical significance < 0.05

*Significant. OR Odds ratio. CI confidence interval. ICU Intensive care unit